TW200619204A - Method for reduction, stabilization and prevention of rupture of lipid rich plaque - Google Patents
Method for reduction, stabilization and prevention of rupture of lipid rich plaqueInfo
- Publication number
- TW200619204A TW200619204A TW094138206A TW94138206A TW200619204A TW 200619204 A TW200619204 A TW 200619204A TW 094138206 A TW094138206 A TW 094138206A TW 94138206 A TW94138206 A TW 94138206A TW 200619204 A TW200619204 A TW 200619204A
- Authority
- TW
- Taiwan
- Prior art keywords
- rupture
- stabilization
- prevention
- reduction
- lipid rich
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 230000009467 reduction Effects 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- VGGMTOYKEDKFLN-UHFFFAOYSA-N 2-[4-[2-(1h-benzimidazol-2-ylsulfanyl)ethyl]piperazin-1-yl]-n-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]acetamide Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)CN1CCN(CCSC=2NC3=CC=CC=C3N=2)CC1 VGGMTOYKEDKFLN-UHFFFAOYSA-N 0.000 abstract 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract 1
- 229960002797 pitavastatin Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63453204P | 2004-12-10 | 2004-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200619204A true TW200619204A (en) | 2006-06-16 |
Family
ID=36587943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094138206A TW200619204A (en) | 2004-12-10 | 2005-11-01 | Method for reduction, stabilization and prevention of rupture of lipid rich plaque |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20090275595A1 (enExample) |
| EP (1) | EP1827440A4 (enExample) |
| JP (1) | JP2008522955A (enExample) |
| KR (1) | KR100895031B1 (enExample) |
| CN (1) | CN101068548B (enExample) |
| AU (1) | AU2005314810B2 (enExample) |
| CA (1) | CA2590224C (enExample) |
| NZ (1) | NZ554924A (enExample) |
| RU (1) | RU2351337C1 (enExample) |
| TW (1) | TW200619204A (enExample) |
| WO (1) | WO2006064889A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060111898A (ko) * | 2003-08-29 | 2006-10-30 | 교와 가부시키가이샤 | 지질-풍부-플라크의 안정화 방법 및 파열 예방방법 |
| US8048083B2 (en) * | 2004-11-05 | 2011-11-01 | Dfine, Inc. | Bone treatment systems and methods |
| WO2011081118A1 (ja) * | 2009-12-29 | 2011-07-07 | 興和株式会社 | 経口投与用医薬組成物 |
| CN102711762A (zh) * | 2009-12-29 | 2012-10-03 | 兴和株式会社 | 口服用固体医药组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
| US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| CZ127198A3 (cs) * | 1995-11-02 | 1998-12-16 | Warner-Lambert Company | Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob |
| US6969711B2 (en) * | 1997-05-26 | 2005-11-29 | Kowa Company, Ltd. | Cyclic diamine compounds and medicine containing the same |
| HUP0002294A3 (en) * | 1997-05-26 | 2001-10-29 | Kowa Co | Cyclic diamine compounds and medicines containing the same |
| RU2235483C2 (ru) * | 1998-11-25 | 2004-09-10 | Нутри Фарма Аса | Композиция, фармацевтический препарат и способ для профилактики и/или лечения и/или ослабления сердечно-сосудистых заболеваний |
| WO2001022962A1 (en) * | 1999-09-30 | 2001-04-05 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
| US6974806B2 (en) * | 2000-07-13 | 2005-12-13 | Takeda Pharmaceutical Company Limited | Lipid-rich plaque inhibitors |
| AU8254101A (en) * | 2000-09-01 | 2002-03-22 | Sankyo Co | Medicinal compositions |
| US20060165605A1 (en) * | 2001-12-28 | 2006-07-27 | Ye-Mon Chen | Process to regenerate fcc spent catalyst |
| MY140618A (en) * | 2003-02-28 | 2009-12-31 | Kowa Co | Method for preparing acid addition salts of polyacidic basic compounds |
| US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
-
2005
- 2005-11-01 TW TW094138206A patent/TW200619204A/zh unknown
- 2005-12-09 CA CA2590224A patent/CA2590224C/en not_active Expired - Fee Related
- 2005-12-09 US US11/721,402 patent/US20090275595A1/en not_active Abandoned
- 2005-12-09 CN CN2005800416162A patent/CN101068548B/zh not_active Expired - Fee Related
- 2005-12-09 KR KR1020077012071A patent/KR100895031B1/ko not_active Expired - Fee Related
- 2005-12-09 JP JP2007526862A patent/JP2008522955A/ja active Pending
- 2005-12-09 AU AU2005314810A patent/AU2005314810B2/en not_active Ceased
- 2005-12-09 NZ NZ554924A patent/NZ554924A/en not_active IP Right Cessation
- 2005-12-09 WO PCT/JP2005/023088 patent/WO2006064889A1/en not_active Ceased
- 2005-12-09 RU RU2007125976/15A patent/RU2351337C1/ru not_active IP Right Cessation
- 2005-12-09 EP EP05816536A patent/EP1827440A4/en not_active Withdrawn
-
2011
- 2011-04-28 US US13/096,477 patent/US20110207742A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005314810B2 (en) | 2010-08-26 |
| EP1827440A1 (en) | 2007-09-05 |
| CA2590224A1 (en) | 2006-06-22 |
| CN101068548B (zh) | 2010-12-08 |
| CN101068548A (zh) | 2007-11-07 |
| RU2007125976A (ru) | 2009-01-20 |
| JP2008522955A (ja) | 2008-07-03 |
| US20110207742A1 (en) | 2011-08-25 |
| HK1111356A1 (en) | 2008-08-08 |
| US20090275595A1 (en) | 2009-11-05 |
| EP1827440A4 (en) | 2010-12-08 |
| KR20070085508A (ko) | 2007-08-27 |
| KR100895031B1 (ko) | 2009-04-24 |
| WO2006064889A1 (en) | 2006-06-22 |
| AU2005314810A1 (en) | 2006-06-22 |
| CA2590224C (en) | 2011-12-20 |
| NZ554924A (en) | 2010-09-30 |
| RU2351337C1 (ru) | 2009-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04002167A (es) | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
| EA200400881A1 (ru) | Азаарилпиперазины | |
| ATE556061T1 (de) | Therapeutisches oder prophylaktisches mittel gegen multiple sklerose | |
| GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
| SI1435915T1 (sl) | Oralne dozirne oblike za propiverin ali njegove farmacevtsko sprejemljive soli s podaljšanim sproščanjem učinkovine | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| EP1545483A4 (en) | NON-NUCLEOSIDIC INHIBITORS OF INVERSE TRANSCRIPTASES | |
| EA200971069A1 (ru) | Метаболиты производных (тио)карбомоилциклогексана | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
| MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
| NO20051892L (no) | Ny forbindelse | |
| ZA202206837B (en) | Compounds for treatment of alzheimer's disease | |
| MXPA04001364A (es) | Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo. | |
| EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
| MXPA06003122A (es) | Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos. | |
| CA2535920A1 (en) | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof | |
| PY0218122A (es) | Metodo para el tratamiento del insomnio primario | |
| MXPA05014143A (es) | Derivados de cumarina para el tratamiento de trastornos oftalmicos. | |
| BR0009080A (pt) | Método de tratamento da apnéia do sono | |
| SE0102887D0 (sv) | New formulation | |
| ATE431147T1 (de) | Mittel zur behandlung des integrationsdysfunktionssyndroms | |
| ATE497761T1 (de) | Therapeutisches oder prophylaktisches mittel gegen leukämie | |
| HUP0401798A2 (hu) | Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására | |
| MEP5608A (xx) | Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli |